Based on Trinity’s 3rd Annual State of Global Market Access white paper, this webinar will take you “around the world” with focused updates on the US, Europe, Asia Pacific, and Latin America. Trinity experts will connect policy and access developments…
Join us for a forward-looking panel discussion featuring experts from Trinity, AstraZeneca, Tris Pharma, and Snowflake. Our panel shares bold predictions for 2026—and explores how Data and AI are reshaping commercial strategy today. The pace of change continues to accelerate…
"This is the gold standard approach to segmentation." —Trinity Life Sciences' client and repeat Weave user Life sciences companies often struggle with fragmented data, complex segmentation solutions, and difficulty translating analytical segments into actionable engagement strategies. Join…
Available On Demand As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating…
Medical Affairs teams are under growing pressure to deliver faster insights, smarter engagement, and measurable value—yet many are limited by manual processes, fragmented data, and time-intensive workflows. Join us for the next webinar in our “AI Innovations in Life Sciences” series, where Trinity experts will show how it is possible with AI to unlock deeper, novel insights, power efficient workflows, and drive greater impact in the Medical Affairs field and headquarters functions.
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Available On Demand Join us for the first webinar in our “AI Innovations in Life Sciences” series to learn how generative AI (GenAI) can transform the way customer-facing teams (sales reps and medical science liaisons) operate in life sciences companies…
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE's proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Today's launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.